argenx | argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG We are pleased to share an important update from argenx regarding the treatment landscape for generalized myasthenia gravis (gMG). The U.S. Food and Drug Administration (FDA) has approved a label expansion for VYVGART (efgartigimod… Read more »
Posts Categorized: blog
Monica Seles Speaks Out About Living with Myasthenia Gravis and partners with argenx in the Go for Greater initiative
Nine-time Grand Slam champion Monica Seles has revealed her diagnosis with myasthenia gravis (MG), which she has been living with since 2022. She first noticed symptoms such as double vision and weakness in her arms and legs, which made everyday tasks difficult, and is now using her platform to educate and support others. Partnering… Read more »
Argenx announces innovative pre-filled syringe self-injection option for adults with gMG
VYVGART Hytrulo prefilled syringe for self-injection (single-dose subcutaneous injection: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase) has been approved by the U.S. FDA for the treatment of adults with anti-AChR antibody-positive generalized myasthenia gravis (gMG). The VYVGART Hytrulo prefilled syringe is a self-injection that takes about 20-30 seconds.* It is injected under the skin (subcutaneously). Patients and/or their caregivers will receive in-person… Read more »
